MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

CSBR

5.84

+2.46%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

CSBR

5.84

+2.46%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

CSBR

5.84

+2.46%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

CSBR

5.84

+2.46%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

CSBR

5.84

+2.46%↑

Home・Elenco Azioni・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

24.83 0.53

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

24.61

Massimo

24.99

Metriche Chiave
By Trading Economics
Entrata	-85K 53M
Vendite	4.2M 153M
P/E Media del settore	14.155 56.063
EPS	0.68
Margine di Profitto	34.53
Dipendenti	182
EBITDA	612K 81M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+45.08% upside

Dividendi
By Dow Jones
Utili prossimi	6 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-41M 2.9B
Apertura precedente	24.3
Chiusura precedente	24.83

Notizie sul Sentiment di mercato

By Acuity

34%

66%

97 / 349 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

N/A / 24.28 Supporto e resistenza

Catalyst Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

31 mar 2026, 23:31 UTC

Azioni calde

Stocks to Watch: Nike, RH, NCino

31 mar 2026, 22:35 UTC

Utili

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 apr 2026, 00:00 UTC

Acquisizioni, Fusioni, Takeovers

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 mar 2026, 23:50 UTC

Acquisizioni, Fusioni, Takeovers

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 mar 2026, 23:43 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 mar 2026, 23:33 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 mar 2026, 23:21 UTC

Utili

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 mar 2026, 23:14 UTC

Discorsi di Mercato

Utili

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 mar 2026, 23:12 UTC

Discorsi di Mercato

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 mar 2026, 22:36 UTC

Utili

China Vanke 2025 Loss Widens >000002.SZ

31 mar 2026, 22:36 UTC

Utili

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 mar 2026, 22:36 UTC

Utili

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 mar 2026, 22:36 UTC

Utili

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 mar 2026, 22:36 UTC

Utili

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 mar 2026, 21:46 UTC

Acquisizioni, Fusioni, Takeovers

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 mar 2026, 21:36 UTC

Discorsi di Mercato

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 mar 2026, 21:35 UTC

Utili

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 mar 2026, 21:35 UTC

Utili

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 mar 2026, 21:35 UTC

Utili

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 mar 2026, 21:33 UTC

Acquisizioni, Fusioni, Takeovers

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mar 2026, 21:33 UTC

Utili

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 mar 2026, 21:32 UTC

Utili

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 mar 2026, 21:28 UTC

Utili

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 mar 2026, 21:26 UTC

Utili

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 mar 2026, 21:25 UTC

Utili

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 mar 2026, 21:24 UTC

Discorsi di Mercato

Utili

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 mar 2026, 21:22 UTC

Utili

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 mar 2026, 21:22 UTC

Utili

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 mar 2026, 21:21 UTC

Utili

Nike's Digital Channel Still Too Promotional, CFO Says

31 mar 2026, 21:20 UTC

Utili

Nike CEO: Converse Remains Important to Portfolio

Confronto tra pari

Modifica del prezzo

Catalyst Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

45.08% in crescita

Previsioni per 12 mesi

Media 34.5 USD 45.08%

Alto 35 USD

Basso 33 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

5 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 5 che hanno fornito valutazioni azionarie a Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

N/A / 24.28Supporto e resistenza

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

97 / 349 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.